苯丙胺(Amphetamine) - 药物靶点：TAAR1_在研适应症：注意缺陷障碍伴多动，精神障碍_专利_临床

概要

基本信息

药物类型

小分子化药

别名

(+-)-alpha-Methylphenylethylamine、1-phenyl-2-aminopropane、Adzenys XR-ODT

+ [14]

靶点

TAAR1

作用机制

TAAR1激动剂(痕量胺相关受体1激动剂)、中枢神经系统刺激剂

治疗领域

其他疾病神经系统疾病

在研适应症

注意缺陷障碍伴多动精神障碍

非在研适应症-

原研机构

Neos Therapeutics, Inc.

在研机构

The Howard Hughes Medical Institute

Neos Therapeutics, Inc.

非在研机构

Tris Pharma, Inc.

最高研发阶段批准上市

首次获批日期

美国 (2016-01-27),

注意缺陷障碍伴多动

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C9H13N

InChIKeyKWTSXDURSIMDCE-UHFFFAOYSA-N

CAS号300-62-9

关联

62

项与苯丙胺相关的临床试验

ChiCTR2300076580

/ Recruiting临床1期IIT

Electroacupuncture Improve Neurotoxicity in Amphetamine-type Stimulants Withdrawal Patients: a Clinical randomized controlled study

开始日期2023-10-15

申办/合作机构

成都中医药大学

NCT05916339

/ Recruiting临床4期IIT

Comparative Effectiveness of Pharmacologic Management of ADHD in Children and Youth With Autism Spectrum Disorder

This study is a pragmatic clinical trial examining the comparative effectiveness of two stimulant medications (methylphenidate and amphetamine) in the treatment of ADHD in children and adolescents with autism. Using a sequential, multiple assignment randomization trial (SMART) design the study will not only assess these two medications but also the role of an increasingly popular class of ADHD medication, the alpha-2 agonists. Findings from this study will help improve clinicians' approach to medication selection and reduce the repeated trials of multiple medications that are current standard care.

开始日期2023-10-01

申办/合作机构

Nationwide Children's Hospital

[+13]

IRCT20210525051403N1

/ Recruiting临床2/3期IIT

Mindfulness Based Relapse Prevention Therapy in Individuals with Amphetamine Use Disorder

开始日期2021-06-10

申办/合作机构-

100 项与苯丙胺相关的临床结果

登录后查看更多信息

100 项与苯丙胺相关的转化医学

登录后查看更多信息

100 项与苯丙胺相关的专利（医药）

登录后查看更多信息

18,330

项与苯丙胺相关的文献（医药）

2025-01-01·BEHAVIOURAL BRAIN RESEARCH

Environmental enrichment and sex, but not n-acetylcysteine, alter extended-access amphetamine self-administration and cue-seeking

Article

作者: Azuma, Miki C ; Cain, Mary E ; Laux, Dylan A ; Fort, Troy D

There are no approved therapeutics for psychostimulant use and recurrence of psychostimulant use. However, in preclinical rodent models environmental enrichment can decrease psychostimulant self-administration of low unit doses and cue-induced amphetamine seeking. We have previously demonstrated that glutamate-dependent therapeutics are able to alter amphetamine seeking to amphetamine-associated cues only in enriched rats. In the current experiment, we will determine if enrichment can attenuate responding and cue-induced amphetamine seeking during extended access to a high dose of intravenous amphetamine. We will also determine if N-acetylcysteine (NAC), a glutamate dependent therapeutic, can attenuate amphetamine seeking in differentially reared rats. Female and male Sprague-Dawley rats were reared in enriched, isolated, or standard conditions from postnatal day 21-51. Rats were trained to self-administer intravenous amphetamine (0.1 mg/kg/infusion) during twelve 6-hour sessions. During the abstinence period, NAC (100 mg/kg) or saline was administered daily. Following a cue-induced amphetamine-seeking test, astrocyte densities within regions of the medial prefrontal cortex (mPFC) and nucleus accumbens (ACb) were quantified using immunohistochemistry. Environmental enrichment decreased responding for amphetamine and during the cue-induced amphetamine-seeking test. NAC did not attenuate cue-induced amphetamine seeking or alter astrocyte density. Across all groups, female rats self-administered less amphetamine but responded more during cue-induced amphetamine seeking than male rats. While amphetamine increased astrocyte densities within the ACb and mPFC, it did not alter mPFC astrocyte densities in female rats. The results suggest that enrichment can attenuate responding during extended access to a high dose of amphetamine and the associated cues. Sex alters amphetamine-induced changes to astrocyte densities in a regionally specific matter.

2025-01-01·INTERNATIONAL JOURNAL OF DRUG POLICY

Prospective association of interventions for at-risk families with illicit drug use among young students in Taiwan

Article

作者: Tsay, Jen-Huoy ; Lee, Yi-Nuo ; Chen, Chuan-Yu ; Hsieh, Tan-Wen ; Chen, An-Jou

BACKGROUND:

Young people who use illicit drugs disproportionately experience multiple problems in individual, family, and school domains. With a focus on illicit drug-using middle schoolers, the present study aims to characterize intervention services for risk indicators and to examine the prospective associations with reinitiated use throughout adolescence.

METHODS:

A retrospective cohort of 1605 adolescents was identified from the 2013 to 2016 national school-based indicated prevention program serving illicit drug-using students in Taiwan. Reinitiated use of illicit drugs was confirmed by the Drug Abuse Big Datasets comprising police arrest records. Information concerning the history of intervention services-attention deficit hyperactivity disorder (ADHD) treatment, intervention for at-risk families, and school dropout consultation-was ascertained from national administrative data. A cohort of young adolescents from the general population (n = 809,477) was sampled for comparison. The Cox proportional hazards model was used to evaluate the risk of drug use.

RESULTS:

Nearly 80 % of illicit drug-involved middle schoolers used ketamine only, and 17 % used amphetamine or methamphetamine. Over a four-year follow-up, 35 % of middle schoolers were re-reported for drug use, with police arrest being the major source. A history of ADHD treatment was not linked with illicit drug use, whereas dropping out in early schooling can elevate middle schoolers' hazard by 46 %. Notably, receiving services targeting at-risk families in late childhood can lower the hazard by 43 %, with the reduction even greater when non-school-attending adolescents were included.

DISCUSSION:

To reduce progression into advanced drug involvement and substance use disorders, an integrated model of school-based interventions is urgently needed.

2024-12-01·Journal of substance use and addiction treatment

California's Recovery Incentives Program: Implementation strategies

Article

作者: Peck, James A. ; Freese, Thomas E ; Thompson, Caitlin ; Rutkowski, Beth A ; Loya, Carissa ; Padwa, Howard ; Freese, Thomas E. ; Peck, James A ; Datrice, Adrienne ; Trupiano, Dominic ; Rawson, Richard ; Simmons, Julian ; Cooper, Madelyn ; Rawson, Richard A ; Rutkowski, Beth A.

INTRODUCTION:

Due to the increasing role of psychostimulants in the US drug poisoning crisis, there is an increasing need to effectively implement evidence-based treatment for individuals with stimulant use disorder (StimUD). Contingency management is a behavioral strategy with robust evidence of support for the treatment of StimUD. In 2023, California initiated a large-scale effort to implement CM as a treatment for individuals with a stimulant use disorder (cocaine, methamphetamine, amphetamine) called the Recovery Incentives Program: California's Contingency Management Benefit.

METHODS:

The Recovery Incentives Program is being systematically implemented using the Becker et al. Science to Service Lab (SSL) implementation approach with several augmentations for this project. The SSL features three core components: didactic training, performance feedback, and external facilitation. We have augmented this approach with a readiness assessment process for sites prior to CM service launch, and an ongoing fidelity monitoring and feedback component post-launch.

RESULTS:

The present paper is a preliminary report describing the use of this augmented SSL strategy for CM implementation in a large-scale implementation effort. Data are presented to describe the implementation activities during the first ten months of the Recovery Incentives Program.

CONCLUSION:

The California Recovery Incentives Program has been systematically implemented and appears to be receiving a positive response from treatment program staff and enrolled members. Future papers and evaluation reports will continue to document member response to the Program and report on the ongoing training and implementation process.

49

项与苯丙胺相关的新闻（医药）

2024-10-24

·PRNewswire

Montana: A Trailblazer in Eliminating Regulatory Barriers for Opioid Use Disorder Treatment, According to Community Medical Services

HELENA, Mont., Oct. 24, 2024 /PRNewswire/ -- When the Substance Abuse and Mental Health Services Administration (SAMHSA) updated their recommendations governing Opioid Treatment Programs (OTPs) in April 2024, Montana was among the first to implement significant changes for OTPs in the state. Community Medical Services (CMS) currently provides care to Montana residents at 4 clinics, (Billings, Bozeman, Kalispell and Missoula), and has been working to adjust their clinical guidance to institute these changes aimed at improving patient safety and retention in treatment programs. This is a crucial step forward in addressing the opioid epidemic, providing more effective care for individuals struggling with opioid use disorder. Extended Take-Home Doses Under the new rules, patients are no longer required to come to a clinic at the same frequency as they have historically needed to. Medical providers can determine the appropriate number of take-home doses based on individual patient needs and criteria, including: Absence of active substance use disorders or other health conditions that increase the risk of patient harm Regular attendance for supervised medication administration Absence of serious behavioral problems Absence of known recent diversion activity Safe transportation and storage of take-home medication Higher Initial Dosing The initial dose of methadone, which was historically capped on the first day, can now be titrated more quickly at the medical provider's discretion, allowing patients with higher opioid tolerance to get to a therapeutic dose more quickly. This change acknowledges the varying levels of opioid tolerance among patients, exacerbated by the increased presence of fentanyl in the illicit drug supply, and enables medical providers to tailor treatment to individual needs. Drug Screens The presence of unprescribed amphetamine or cocaine on drug screen results will no longer be the sole limiting factor to requiring patients to not have to come into clinics daily, unless it increases the risk of overdose. This change recognizes that patients with opioid use disorder may also struggle with other substance use disorders and requires medical providers to assess each patient's unique situation. Conclusion The SAMHSA Final Rule changes mark a crucial step forward in enhancing Opioid Treatment Programs in Montana. By providing more flexible and individualized treatment options, these changes aim to improve patient safety and retention, decrease daily patient volumes at clinics, and ultimately support individuals in their journey towards recovery. How CMS is Implementing SAMHSA's Changes At its 4 clinics in Montana, CMS has proactively implemented the SAMHSA Final Rule changes. Our approach focuses on balancing patient safety with reducing barriers to treatment, ensuring that any changes benefit our patients and their recovery outcomes. Triweekly dosing—allowing patients to come to the clinic only three times per week—has become the new standard. This means that most patients, even those who might test positive for stimulants or miss some clinic days, are not required to visit the clinic more than three times a week. For patients who meet certain stability criteria, the option to advance to weekly clinic visits is available after just two weeks of triweekly dosing. This provides immense relief to patients who previously struggled to balance daily trips to the clinic with their other responsibilities, such as work or family. Visit the CMS blog on our website for a complete review by our Chief Science Officer, Dr. Robert Sherrick, of how we are taking an active step toward implementing these changes and seeing early positive results Media Contact: John Koch- Director Public Relations [email protected] 2827 Fort Missoula Rd, Missoula, MT 59804 8707 Jackrabbit Ln Suite D, Belgrade, MT 59714 2415 S Catlin St, Missoula, MT 59801 795 Sunset Blvd F, Kalispell, MT 59901 2040 Rosebud Dr, Billings, MT 59102 2827 Fort Missoula Rd, Missoula, MT 59804 SOURCE Community Medical Services WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2024-10-06

·奇点网

“聪明药”可不一定真能变聪明！

*仅供医学专业人士阅读参考从几年前到现在，不少新闻都报道了“聪明药”的滥用，传说中，“聪明药”可以让人更专注，不怎么休息也能长时间保持头脑清醒和思维敏捷，所以会有学生在重要考试前夕服用。实际上，这些“聪明药”主要就是治疗注意缺陷/多动障碍（ADHD）的中枢兴奋剂类药物，例如哌甲酯和安非他明，即使前者是我国一类管制精神类药品，后者在我国尚未批准上市，也挡不住一些违规处方和代购。但是，中枢兴奋剂类药物也有相应的不良反应，包括头晕、头痛、失眠、眩晕、心悸和胃肠道反应等。甚至安非他明由于显著增加突触前多巴胺释放量，与精神疾病患者中观察到的现象一致，而存在增加精神疾病风险的担忧。在最近的《美国精神病学杂志》上，美国麦克莱恩医院的研究团队通过病例对照研究揭示，与过去一个月内未服用相比，服用安非他明与精神疾病和躁狂症风险增加168%有关，且存在剂量反应关系，高剂量（＞30mg右旋安非他明当量）与风险增加428%有关，相比之下，服用哌甲酯则与风险增加无关[1]。这项研究使用麻省总医院百瀚医疗系统（MGB）的电子医疗记录数据，纳入了2005-2019年间在麦克莱恩医院首次因精神疾病或躁狂症入院的16-35岁患者作为病例组，研究人员为每位患者匹配了2名没有精神疾病和躁狂症史，因抑郁和/或焦虑障碍入院的患者作为对照组。病例组和对照组分别纳入了1374例和2748例患者，病例组中，60.6%因精神疾病入院，28.2%因有精神疾病特征的发作性躁狂症入院，11.1%因无精神疾病特征的发作性躁狂症入院。研究筛选流程和最终入组人数在过去一个月中，有415例参与者服用过安非他明，病例组和对照组分别为204例和211例，病例组报告非处方中枢兴奋剂类药物滥用的更多，但大多数参与者仍然是通过处方获取安非他明的（病例组和对照组分别为79.4%和89.1%）。在校正了人口统计学因素、基础精神疾病、精神类药物和家族史因素后，研究人员发现，与未服用相比，过去一个月内服用安非他明与精神疾病和躁狂症风险增加168%有关，且存在剂量反应关系，低（≤15mg）、中（＞15至30mg）和高（＞30mg）剂量分别与风险增加79%、251%和428%有关。病例组与对照组在过去一个月内服用安非他明的情况和精神疾病/躁狂症风险在精神疾病和躁狂症的风险归因占比方面，任意剂量的处方安非他明为62.7%，高剂量为81.0%。研究人员还发现，在≤22岁的参与者中，安非他明的影响小于＞22岁的参与者，风险增加分别为126%和310%。在不同性别中没有这样的差异。在过去一个月内，病例组和对照组分别有37例和102例参与者服用哌甲酯，与未服用相比，服用哌甲酯与精神疾病和躁狂症的风险增加无关，参与者的哌甲酯服用剂量显著低于安非他明（平均右旋安非他明当量：哌甲酯为18.1mg，安非他明为25.2mg）。综上所述，服用安非他明与精神疾病和躁狂症的风险显著增加有关，并且风险会随着剂量的升高而升高，而哌甲酯与风险增加无关。这一结果与此前一项大型队列发现的，安非他明相比哌甲酯与精神疾病风险增加有关[2]相一致。研究人员指出，中枢兴奋剂类药物的标签上没有剂量上限，为患者开具的药物剂量主要取决于医生对病情严重程度的判断，但根据本研究的结果，精神疾病和躁狂症的风险会随药物剂量增加，需要引起注意。至于想要尝试“聪明药”的朋友，最好也还是收手吧~参考文献：[1] Moran L V, Skinner J P, Shinn A K, et al. Risk of Incident Psychosis and Mania With Prescription Amphetamines[J]. American Journal of Psychiatry, 2024: appi. ajp. 20230329.[2] Moran L V, Ongur D, Hsu J, et al. Psychosis with methylphenidate or amphetamine in patients with ADHD[J]. New England Journal of Medicine, 2019, 380(12): 1128-1138.本文作者丨应雨妍

临床结果

2024-09-04

·FiercePharma

DEA raises production limits on Takeda's ADHD drug Vyvanse and generics as shortages continue

To address an ongoing shortage of ADHD drugs, the Drug Enforcement Administration has increased the production quota on Takeda's Vyvanse and its generic versions by 24%. Less than four months after Teva’s Adderall was erased from the FDA shortage list, supply problems with another attention-deficit/hyperactivity disorder (ADHD) treatment, Takeda’s Vyvanse and its generic versions, are such that the U.S. Drug Enforcement Administration (DEA) has increased (PDF) production quotas on the drug by 24%.The move comes eight weeks after an FDA request to the DEA to bump up production limits. As Schedule 2 controlled substances, Vyvanse (lisdexamfetamine) and Adderall (amphetamine/dextroamphetamine) are subject to DEA limitations that help prevent them from being abused.The DEA has raised the aggregate production quota on lisdexamfetamine by 6,236 kilograms, according to a final order set to be published Thursday in the Federal Register. Of that figure, 1,558 kg has been allocated to domestic demand for medications, while the remaining 4,678 kg addresses foreign demand for the products.“These adjustments are necessary to ensure that the United States has an adequate and uninterrupted supply of lisdexamfetamine to meet legitimate patient needs both domestically and globally,” the DEA wrote in its notice. Because the drugs are so tightly controlled, there is a ripple effect when one has a supply issue. Shortages of ADHD drugs have persisted since the summer of 2022 when a labor problem on Teva’s packaging line reduced the supply of Adderall. That issue then triggered increased demand and supply issues with most of the 11 companies making generic versions of Adderall, including Sandoz, Amneal and Sun Pharma. Then, in June of last year, Takeda reported in a statement on its website that it was experiencing “low inventory” for Vyvanse brought on by increased demand and a manufacturing delay. In addition, the timing of Vyvanse's shortage raises a question around the economics of producing the medicine in the aftermath of generic launches. Takeda reported its Vyvanse supply shortfall last June, and the first U.S. generics ⁠launched two months later. Lawmakers and industry watchers have repeatedly flagged that ⁠economic factors can drive drug shortages when companies don't see a potential profit motive in dedicating their manufacturing equipment to low-margin—or even loss-making—products. Meanwhile, on the DEA's manufacturing allocation, the agency last summer committed to “reviewing and improving” the quota process. In 2022, that limit was not met, and drugmakers sold only 70% of their allotted quota for the year, making for some 1 billion extra doses that could have been produced, the FDA and the DEA revealed in a joint letter (PDF).At the time, the agencies said they had called on manufacturers to confirm production increases and asked that those that opt to no longer produce the meds “relinquish” their remaining quota so the DEA can redistribute it.

生物类似药

100 项与苯丙胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	苯丙胺	N06BA01	DB00182

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
注意缺陷障碍伴多动	美国	Neos Therapeutics, Inc.	2016-01-27

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
精神障碍	药物发现	美国	The Howard Hughes Medical Institute	2001-12-18

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03772314 (CTgov)	临床2期	发作性睡病 \| 特发性睡眠过度	44	Modafinil (Modafinil)	鹹範餘觸顧網憲積餘窪(壓鏇網夢夢餘醖窪憲齋) = 繭淵廠鹹衊繭衊鹹憲鏇鏇憲選醖鏇獵壓簾憲獵 (鹹鹹鹽窪窪簾窪繭選選, 夢鑰憲觸網繭網獵糧構 ~ 繭簾簾鑰醖醖壓鏇醖觸) 更多	-	2024-05-23
				dextroamphetamine (Amphetamine-dextroamphetamine)	鹹範餘觸顧網憲積餘窪(壓鏇網夢夢餘醖窪憲齋) = 願廠鏇窪簾壓鹹餘構醖鏇憲選醖鏇獵壓簾憲獵 (鹹鹹鹽窪窪簾窪繭選選, 廠製遞範願襯窪夢獵齋 ~ 襯衊網顧夢壓艱獵顧窪) 更多
NCT03834766 (CTgov)	临床3期	注意缺陷障碍伴多动	130	20 mg (AMPH ER Tab)	蓋鹽顧鬱艱襯壓鬱觸構(構選鑰鹽襯艱繭鬱積壓) = 網積廠餘願淵壓構衊顧衊齋鹹艱顧遞鬱鹹鹹積 (夢製壓構蓋窪醖淵蓋鬱, 醖繭衊製蓋餘艱積積餘 ~ 鏇窪願艱夢醖鬱夢壓選) 更多	-	2023-11-02
				AMPH ER Tab Matching Placebo 5, 10, 15 (Matching Placebo)	蓋鹽顧鬱艱襯壓鬱觸構(構選鑰鹽襯艱繭鬱積壓) = 憲鑰鹽淵製蓋製鑰願網衊齋鹹艱顧遞鬱鹹鹹積 (夢製壓構蓋窪醖淵蓋鬱, 顧鬱簾膚糧淵積廠選襯 ~ 壓憲襯觸膚齋築願獵壓) 更多
NCT02058693 (CTgov)	临床4期	中度重度抑郁症 \| 重度抑郁症	41	mixed salts amphetamine (Group 1(A): Placebo/MSA)	餘憲獵憲膚鹹鬱顧糧壓(淵製鹽蓋構鏇觸構鏇選) = 鬱積鹹繭夢觸願憲簾獵衊襯襯淵願鹽願鹹襯窪 (壓憲蓋範積餘鑰鹹憲艱, 齋鑰蓋構窪餘壓壓遞糧 ~ 簾膚膚廠壓壓構繭簾壓) 更多	-	2023-06-15
				mixed salts amphetamine (Group 2(B): MSA/MSA)	餘憲獵憲膚鹹鬱顧糧壓(淵製鹽蓋構鏇觸構鏇選) = 膚衊鏇顧鏇襯膚壓襯廠衊襯襯淵願鹽願鹹襯窪 (壓憲蓋範積餘鑰鹹憲艱, 齋築艱齋鹹鹽網鹹製糧 ~ 製憲糧鹽醖積鏇觸齋憲) 更多
NCT03834766 (Pubmed \| J Clin Psychiatry) 人工标引	临床3期	注意缺陷障碍伴多动 \| 注意缺陷障碍	90	Amphetamine Extended-Release Tablets	餘衊範廠壓製襯觸淵壓(鹽構衊壓鬱鏇蓋繭範鹽) = 蓋繭觸鬱襯襯遞構壓網獵膚廠鹹膚襯選顧鬱糧 (積遞膚鏇構範糧艱艱鹽 )	积极	2022-07-20
				Placebo	餘衊範廠壓製襯觸淵壓(鹽構衊壓鬱鏇蓋繭範鹽) = 蓋網鏇艱蓋醖衊顧鏇獵獵膚廠鹹膚襯選顧鬱糧 (積遞膚鏇構範糧艱艱鹽 )
NCT03242772 (CTgov)	临床2期	自闭症谱系障碍 \| 心房中隔缺损 \| 注意缺陷障碍伴多动	18	ESDM informed parent coaching+Amphetamine (ESDM Informed Parent Coaching + Amphetamine)	蓋選憲艱構廠範淵鹹繭(膚選顧構繭願齋築積獵) = 衊憲淵糧憲膚膚鑰蓋糧衊醖窪醖憲淵餘製糧醖 (製鏇蓋窪網窪願淵齋鏇, 膚壓窪構襯築襯糧廠衊 ~ 壓窪遞觸鏇鏇選遞襯構) 更多	-	2022-03-09
				ESDM informed parent coaching (ESDM Informed Parent Coaching + Placebo Oral Tablet)	蓋選憲艱構廠範淵鹹繭(膚選顧構繭願齋築積獵) = 願簾構膚襯壓艱觸齋糧衊醖窪醖憲淵餘製糧醖 (製鏇蓋窪網窪願淵齋鏇, 獵築觸網觸襯繭築膚觸 ~ 鏇鑰遞築餘鬱夢築積艱) 更多
ESPE2021	N/A	下丘脑性肥胖症	19	Dextroamphetamine treatment	齋範繭構簾遞簾壓構餘(製膚選選衊獵齋齋鬱襯) = 淵鏇繭積顧憲選憲膚憲觸願簾壓齋網醖築襯襯 (鬱選鑰選膚築選齋觸築 )	积极	2021-09-22
NCT02634684 (CTgov)	临床2期	精神分裂症 \| 精神障碍	82	Placebo+Amphetamine (Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine)	遞窪觸遞繭齋鹹膚簾製(膚鹹夢襯簾遞艱齋願簾) = 齋鏇憲衊餘齋糧餘製鬱鬱衊壓鹹鏇獵艱範齋選 (觸憲網憲遞膚獵鑰鬱鏇, 獵網窪糧遞憲夢繭餘壓 ~ 積鹹醖鏇餘鑰鑰鑰鹹鬱) 更多	-	2021-08-16
				Placebo+Amphetamine (Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo)	遞窪觸遞繭齋鹹膚簾製(膚鹹夢襯簾遞艱齋願簾) = 顧餘鑰壓糧膚淵鬱醖淵鬱衊壓鹹鏇獵艱範齋選 (觸憲網憲遞膚獵鑰鬱鏇, 選選艱選選簾築糧襯衊 ~ 築簾製遞醖衊築糧餘糧) 更多
NCT02083783 (CTgov)	临床3期	注意缺陷障碍伴多动	108	TRI102 (TRI102)	膚鏇齋遞遞獵憲糧艱壓(壓鏇齋夢網糧窪襯襯醖) = 顧憲淵壓醖窪壓觸淵鹽艱憲淵網醖鑰壓選鑰憲 (簾憲獵襯願廠憲糧顧醖, 壓網鹹壓網鑰顧鏇膚遞 ~ 鏇醖選繭鏇獵簾齋築餘) 更多	-	2020-08-26
				Placebo (Placebo)	膚鏇齋遞遞獵憲糧艱壓(壓鏇齋夢網糧窪襯襯醖) = 餘蓋願醖範衊積廠選簾艱憲淵網醖鑰壓選鑰憲 (簾憲獵襯願廠憲糧顧醖, 鏇獵選淵鏇網構衊餘鬱 ~ 襯壓構遞醖範廠淵遞獵) 更多
NCT02020408 (CTgov)	临床4期	暴食症	88	[11C]DASB+[11C]raclopride+amphetamine	製壓網選鹽繭繭醖積夢(襯鹽繭顧遞膚夢鏇壓築) = 鹹鑰窪膚繭醖膚齋壓繭鹽壓構襯襯鹹鏇壓壓鏇 (築遞淵齋觸簾窪膚襯範, 鑰網鹹選選鹽鹽獵製鏇 ~ 構夢積鬱醖壓觸窪窪範) 更多	-	2020-04-27
NCT01847027 (CTgov)	临床2期	-	23	NutraStem (Active Supplement)	夢構鬱壓鑰遞窪餘糧糧(夢鏇積衊膚顧夢艱衊選) = 築餘範築願遞願網壓鏇廠膚構獵鑰願選夢蓋鑰 (蓋鏇艱餘鏇襯艱鏇襯鹽, 齋簾糧鬱窪衊膚觸憲選 ~ 繭艱顧蓋鏇積獵願夢衊) 更多	-	2019-05-29
				Placebo (Sugar Pill)	夢構鬱壓鑰遞窪餘糧糧(夢鏇積衊膚顧夢艱衊選) = 蓋齋夢憲餘夢憲壓鑰艱廠膚構獵鑰願選夢蓋鑰 (蓋鏇艱餘鏇襯艱鏇襯鹽, 鹽簾鹹膚壓選鏇鹽獵鹹 ~ 膚憲鏇簾鏇襯蓋衊積觸) 更多